Ekso Bionics Announces New Data to be Presented at 55th ISCoS Annual Scientific Meeting
New data from Pan-Euro Study and other clinical evidence in the field of exoskeleton therapy
RICHMOND, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, today announced that the company and its collaborators will have ten abstracts (one topical paper and nine posters) with data from 116 patients presented at the International Spinal Cord Society (ISCoS) Annual Scientific Meeting taking place September 14-16, 2016 in Vienna, Austria. Of the 116 patients covered by these presentations, data from 54 patients are from the Ekso Bionics-sponsored Pan-Euro Study.
The titles and schedule of posters and presentations are as follows:
Topical Papers 2, 14 Sept 16, 11:40-1:10, Forum (Parallel 3)
Dr. Willemijn Faber, Rehabilitation Physician, Rehab Centre Heliomare: The Eksoskeleton - First clinical experiences with spinal cord injury patients and measurement of their energy expenditure in the Netherlands.
Poster Presentations (all in Exhibition/Poster/Catering Area):
Session 1, 14 Sept 16, 10:35 - 11:35 and 3:10 - 4:10
- Mrs. Helene Nilsson, Physiotherapist, Department of Rehabilitation Medicine, Uppsala University Hospital: Effects of overground gait training, using the robotic-exoskeleton Ekso™ and assessment of gait parameters using the GAITRite®system. A pilot study. Abstract #382
- Dr. Ashraf Gorgey, Director of The Research, Hunter Holmes Mcguire VA Medical Center: Exoskeleton Training and Physical Activity after Spinal Cord Injury: A Case Series. Abstract #281
Session 2, 15 September 16, 9:50 - 10:45 and 3:10-4:10
- Dr. Ulla vig Nissen, Post Doc., Clinic For Spinal Cord Injuries: Gait progression in the Ekso™ robotic exoskeleton after eight weeks training in participants with Spinal Cord Injury (Pan-Euro Study). Abstract #172.
- Dr. Ashraf Gorgey, Director of The Research, Hunter Holmes Mcguire VA Medical Center: Exoskeletons and Rehabilitation after Spinal Cord Injury. Abstract #410.
- Dr. Giulia Stampacchia, Medical Director Centro Mielolesi, Medtronic: Psychological and physical effort during robotic exoskeleton assisted walking on treadmill and overground in SCI persons. Abstract #197.
Session 3, 16 Sept 16, 9:50-10:50 and 12:30-1:30
- Dr. Enrica Bonatti, Doctor, Montecatone Rehabilitation Institute: Locomotor Training With Exoskeleton EKSO-GT in Patients With Incomplete Motor Spinal Cord Injury in a Hospital Setting- Preliminary Results. Abstract #199.
- Miss Kirsty Luard, Physiotherapy Specialist, Hobbs Rehabilitation: A study exploring the clinical effects of a short-duration exoskeleton rehabilitation programme on key physiological markers in spinal cord injury. Abstract #420.
- Mrs. Joanna Roziak, Physiotherapist, Technomex: Results after six month of therapy using new robotic devices after spinal cord injury: a case study. Abstract #430.
- Mrs. Katherine Strausser, Sr. Controls Engineer, Ekso Bionics Europe GmbH: Safety and Efficacy of High-Dosage Use of Exoskeleton in Home Environment for Chronic SCI: A Pilot Study. Abstract #67.
There will be eight additional posters at ISCoS that address the functioning and benefits of exoskeletons in general. For more detailed information, please visit:
Ekso Bionics will be exhibiting at booth numbers 13 and 15.
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
About Ekso™ GT
Ekso™ GT is the first FDA cleared exoskeleton cleared for use with stroke and spinal cord injuries from L5 to C7. The Ekso GT with smart Variable Assist™ (marketed as SmartAssist outside the U.S.) software is the only exoskeleton available for rehabilitation institutions that can provide adaptive amounts of power to either side of the patient’s body, challenging the patient as they progress through their continuum of care. The suit’s patented technology provides the ability to mobilize patients earlier, more frequently and with a greater number of high intensity steps. To date, this device has helped patients take more than 55 million steps in over 120 rehabilitation institutions around the world.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.
Media Contact: Carrie Yamond/Rajni Dhanjani 212-867-1788 firstname.lastname@example.org Investor Contact: Debbie Kaster 415-937-5403 email@example.com
Released September 12, 2016